Monitoring disease progression using high-density motor unit number estimation in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 42, Issue 2, 2010, Pages 239-244

  Van Dijk, Johannes P ^a   Schelhaas, Helenius J ^a   Van Schaik, Ivo N ^b   Janssen, Henny M H A ^a   Stegeman, Dick F ^a,c   Zwarts, Machiel J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

ALS; Follow up; High density EMG; MUNE; Stratify

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CORRELATION COEFFICIENT; DISEASE COURSE; INTERMETHOD COMPARISON; MOTOR UNIT; MUSCLE ACTION POTENTIAL; PRIORITY JOURNAL; RATING SCALE; REPRODUCIBILITY;

ACTION POTENTIALS; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR NEURONS; MUSCLE STRENGTH; MUSCLE, SKELETAL; NERVE DEGENERATION;

EID: 77955126418     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21680     Document Type: Article

References (31)

1. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler 2008;9:16-23. (Pubitemid 351260368)
2. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-27. (Pubitemid 44305456)
3. Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, Macarthur RB, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008;9:212-222.
4. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330: 585-591. (Pubitemid 24065791)
5. Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008;5: 516-527.
6. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94-109.
7. Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9:163-167. (Pubitemid 351983177)
8. Shefner JM. Motor unit number estimation in human neurological diseases and animal models. Clin Neurophysiol 2001;112:955-964.
9. McComas AJ, Fawcett PR, Campbell MJ, Sica RE. Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry 1971;34:121-131.
10. Blok JH, van Dijk JP, Zwarts MJ, Stegeman DF. Motor unit action potential topography and its use in motor unit number estimation. Muscle Nerve 2005;32:280-291.
11. van Dijk JP, Blok JH, Lapatki BG, van Schaik IN, Zwarts MJ, Stegeman DF. Motor unit number estimation using high-density surface electromyography. Clin Neurophysiol 2008;119:33-42.
12. van Dijk JP, Zwarts MJ, Schelhaas HJ, Stegeman DF. Effect of small motor unit potentials on the motor unit number estimate. Muscle Nerve 2008;38:887-892.
13. Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 1997;20:179-185. (Pubitemid 27061530)
14. Arasaki K, Kato Y, Hyodo A, Ushijima R, Tamaki M. Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve 2002;25:520-526. (Pubitemid 34293126)
15. Wang FC, Delwaide PJ. Number and relative size of thenar motor units estimated by an adapted multiple point stimulation method. Muscle Nerve 1995;18:969-979.
16. Lapatki BG, van Dijk JP, Jonas IE, Zwarts MJ, Stegeman DF. A thin, flexible multielectrode grid for high-density surface EMG. J Appl Physiol 2004;96:327-336.
17. van Dijk JP, Lowery MM, Lapatki BG, Stegeman DF. Evidence of potential averaging over the finite surface of a bioelectric surface electrode. Ann Biomed Eng 2009;37:1141-1151.
18. Merkies IS, Schmitz PI, Samijn JP, Meche FG, Toyka KV, van Doorn PA. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000;23: 1393-1401.
19. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 1997;152(suppl 1):S1-S9. (Pubitemid 27505283)
20. Albrecht E, Kuntzer T. Number of Edb motor units estimated using an adapted multiple point stimulation method: normal values and longitudinal studies in ALS and peripheral neuropathies. Clin Neurophysiol 2004;115:557-563. (Pubitemid 38230981)
21. Liu XX, Zhang J, Zheng JY, Zhang S, Xu YS, Kang DX et al. Stratifying disease stages with different progression rates determined by electrophysiological tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 2009;39:304-309.
22. Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve 1999;22: 1571-1575. (Pubitemid 29508308)
23. Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang MX, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007;68:1402-1410.
24. Major LA, Hegedus J, Weber DJ, Gordon T, Jones KE. Method for counting motor units in mice and validation using a mathematical model. J Neurophysiol 2007;97:1846-1856. (Pubitemid 46239551)
25. Henderson RD, Ridall PG, Hutchinson NM, Pettitt AN, McCombe PA. Bayesian statistical MUNE method. Muscle Nerve 2007;36: 206-213.
26. de Carvalho M, Swash M. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol 2006;63:557-560.
27. Maathuis EM, Drenthen J, van Dijk JP, Visser GH, Blok JH. Motor unit tracking with high-density surface EMG. J Electromyogr Kinesiol 2008;18:920-930.
28. Yuen EC, Olney RK. Longitudinal study of fiber density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology 1997;49:573-578. (Pubitemid 27368904)
29. McComas AJ, Sica RE, Campbell MJ, Upton AR. Functional compensation in partially denervated muscles. J Neurol Neurosurg Psychiatry 1971;34:453-460.
30. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurology 2004;63: 1656-1661.
31. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve 2007;35:228-234. (Pubitemid 46247162)